# Kaibao Zhiyuan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kaibao-zhiyuan

- Headquarters: Shanghai, China
- Latest round: Seed (May 21, 2026)
- Investors on record: 1

## About

Based in Shanghai, China, and founded in 2025, Shanghai Kaibao Zhiyuan Biotechnology Co., Ltd., trading as Kaibao Zhiyuan, operates in biotechnology R&D and pharmaceutical technology development. In May 2026, Kaibao Zhiyuan raised a Seed funding from Pudong Capital.
The company’s core offerings are proprietary transdermal and transmucosal drug delivery technology platforms covering purification, permeation enhancement, functional preservation, and quantitative quality control.
The company primarily generates revenue from providing biotechnology R&D services and drug delivery technology solutions.
The Seed round of funding will be primarily used for the R&D and preclinical validation of core product pipelines, the construction of GMP processes and quality control systems, market expansion, and the development of the core team, further consolidating the company's core competitiveness in the innovative drug delivery sector and accelerating the large-scale deployment of products.

## Funding rounds

- Seed, May 21, 2026 — Pudong Capital

## Investors

- Pudong Capital (https://capitalatlas.ai/funds/pudong-capital) — Seed